Physician profile
Gary Cooperstein
NPI 1023010006
$2,620.70
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2021: $63.64 · 2022: $738 · 2023: $871 · 2024: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $414.94 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $360.92 | 2022-2024 | Otezla, Repatha |
| Novo Nordisk INC | $283.80 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $202.30 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.28 | 2023-2024 | |
| Exact Sciences Corporation | $136.47 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $129.66 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $119.67 | 2023-2024 | |
| Amarin Pharma, INC. | $97.72 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.81 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $76.49 | 2019 | |
| Idorsia Pharmaceuticals US INC | $68.10 | 2022-2024 | Quviviq |
| Abbott Laboratories | $63.47 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $55.54 | 2023-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $40.22 | 2024 | Prospera |
| Almatica Pharma LLC | $40.21 | 2021-2022 | |
| Phadia US INC. | $36.40 | 2022-2024 | Immunocap |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.58 | 2022 | |
| Astellas Pharma US INC | $26.34 | 2023 | Veozah |
| Gilead Sciences, INC. | $20.87 | 2022 | |
| Dexcom, INC. | $17.87 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $16.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.00 | 2024 | Nuzyra |
| Genentech USA, INC. | $15.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.52 | 2022 | |
| Boston Scientific Corporation | $14.98 | 2023 | Watchman Flx |
| Lucid Diagnostics INC. | $12.57 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cooperstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.